Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carbidopa monohydrate; Levodopa
Sandoz Ltd
N04BA02
Carbidopa monohydrate; Levodopa
50mg ; 200mg
Modified-release tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04090100; GTIN: 5050650044027
OBJECT 1 LECADO 200/50 MG MODIFIED-RELEASE TABLETS Summary of Product Characteristics Updated 08-Feb-2018 | Sandoz Limited 1. Name of the medicinal product Lecado 200/50 mg Modified-release Tablets 2. Qualitative and quantitative composition Each prolonged-release tablet contains 200 mg levodopa and 50 mg carbidopa (as carbidopa monohydrate). For a full list of excipients, see section 6.1. 3. Pharmaceutical form Prolonged-release tablets Appearance: Orange-brown, round, biconvex tablets 4. Clinical particulars 4.1 Therapeutic indications Idiopathic Parkinson's disease, in particular to shorten the 'off' period in patients who have previously been treated with immediate-release levodopa/decarboxylase inhibitors or with just levodopa and who showed motor fluctuations. Experience with Lecado is limited in patients, who have not been previously treated with levodopa. 4.2 Posology and method of administration The daily dose of levodopa/carbidopa should be carefully determined. Patients should be monitored closely during the period of dose adjustment, especially with regard to the occurrence or exacerbation of nausea and abnormal involuntary movements, such as dyskinesia, chorea and dystonia. Blepharospasm could be an early sign of overdosing. The pharmacokinetic properties of the prolonged-release tablets may be altered if the tablets are broken or chewed. Therefore the tablets must be swallowed whole. Most other medicines, used to treat Parkinson's Disease, except for levodopa, can be continued during administration of levodopa/carbidopa. However their dosage may need to be adjusted. Sudden withdrawal of Lecado therapy should be avoided wherever possible. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, Lecado 200/50 mg can be administered to patients who receive supplemental pyridoxine (Vitamin B 6 ). • Starting dose Patients who have never before received Levodopa therapy Lecado 100/25 mg is designed for use in patients, who have not previously had levodopa treatment or to aid titra Read the complete document